Fed holds interest rates steady, but a cut is expected in coming months; NBI added 7 %

Werewolf Therapeutics 

Short interest of Werewolf increased by 116 % to 1,051,758 reported on July 15, compared to 487,913 on June 14. The share price may likely drop in upcoming weeks. 

Allogene Therapeutics 

Allogene announced that Rocky Mountain Cancer Centers, part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, a multi-specialty community oncology practice and part of the OneOncology network; and Norton Cancer Institute, are open for enrollment in the pivotal Phase 2 ALPHA3 trial. 

Autolus Therapeutics 

Autolus announced it will release its second quarter 2024 financial results and operational highlights before the opening of US markets on August 8. Short interest of Autolus increased by 85 % to 11,901,308 reported on July 15, compared to 6,428,136 on June 14. The share price may likely drop in upcoming weeks. 

Arcellx 

The company’ s CFO Michelle Gilson sold 12,877 shares of Arcellx, decreasing her position in the company by 65 %. 

Mustang Bio 

Short interest of Mustang increased by 86 % to 1,267,933 reported on July 15, compared to 680,992 on June 14. The share price may likely drop in upcoming weeks. 

Immutep 

Immutep announced it has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase 1 study of IMP761. IMP761 is the world’s first therapeutic LAG-3 agonist antibody and as such is uniquely positioned in the treatment landscape for autoimmune diseases. Separately, it also announced that positive feedback has been received from FDA regarding the planned TACTI-004 Phase 3 trial of efti in combination with Keytruda and histology-based platinum doublet chemotherapy for the treatment of first-line metastatic NSCLC, regardless of PD-L1 expression. 

MacroGenics 

Short interest of Macrogenics decreased by 29 % to 7,741,295 reported on July 15, compared to 10,864,124 on June 14. The share price may likely rise in upcoming weeks. The company also announced the achievement of $100 million in milestones from Incyte related to development progress of Zynyz (retifanlimab-dlwr). Zynyz is an intravenous PD-1 inhibitor indicated in the US for treatment of metastatic or recurrent locally advanced Merkel cell carcinoma.